Lyme Disease Vaccine
If the fear of ticks prevents you from enjoying the great outdoors, there might be some good news on the horizon. Thomas Lingelbach with Valneva has been working on a new vaccine designed to ward off Lyme disease.
Inside the Arena Makeover | Kevin Lind, CFO, Arena Pharmaceuticals
Up until about three years ago Kevin Lind would likely have been identified as yet another gifted private equity executive – capable of issuing business remedies from the tip of his tongue. At least in the minds of his CFO peers, who are accustomed to listening to PE pundits routinely hand down such remedies [...]
Oxurion CEO discusses expertise in treating diabetic eye disease and the company’s robust pipeline
Patrik De Haes, MD is CEO of Oxurion (Oxurion.com). Their first major success was cardiac drug tPA; today, Jetrea is their first commercialized product for diabetic eye disease, with three new molecules for diabetic eye disease in development.
Orchard Looks toward Harvesting Expanded Gene Therapy Pipeline – Global Genes
It was about ten months ago that Orchard Therapeutics acquired the gene therapy portfolio of GSK, expanding its pipeline and giving it its first approved therapy. We spoke to Orchard CEO Mark Rothera about his company’s approach to gene therapy, its pipeline, and what he sees as the biggest challenges as Orchard moves towards [...]
Robust Pipeline for Treatments for Diabetic Eye Disease with Dr. Patrik De Haes Oxurion
Dr. Patrik De Haes, CEO, Oxurion discusses the need for new treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.
New Treatment for Obsessive-Compulsive Disorder with Dr. Nolan Williams
Dr. Nolan Williams, Clinical Assistant Professor of Psychiatry and Behavioral Sciences at Stanford University. We speak about new treatment options for use in treatment-resistant patients with OCD, including brain stimulation. A deep TMS device was recently FDA approved for the treatment of treatment-resistant OCD.
Is Hearing Loss a Necessary Price for Children to Pay for Life-Saving Chemotherapies
We spoke to Nawal Ouzren, CEO of Sensorion, which will participate in the FDA meeting and is developing a treatment for sudden hearing loss that may be able to help pediatric cancer patients experiencing cisplatin-induced ototoxicity.
The Case for a Daily Self-Injection to Treat Hemophilia
We spoke to Nassim Usman, CEO of Catalyst, about the company’s approach to hemophilia, how its drugs work, and why he believes his company’s pipeline may provide better alternatives for hemophilia patients.
Bloomberg Markets: ICO Compliance, Drug Development
Amit Munshi President/CEO Arena Pharmaceuticals Inc Discussing drug development in ulcerative colitis space.